抗血管生成疗法：将这种新型治疗方式与实体癌放化疗相结合的潜在作用。
Antiangiogenics: the potential role of integrating this novel treatment modality with chemoradiation for solid cancers.
作者信息
Duda Dan G, Jain Rakesh K, Willett Christopher G
机构信息
Steele Laboratory, Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA 02114, USA.
出版信息
J Clin Oncol. 2007 Sep 10;25(26):4033-42. doi: 10.1200/JCO.2007.11.3985.
Abstract
Although still in very early stages of clinical development, the combination of antiangiogenics with contemporary chemoradiotherapy regimens has emerged as a feasible and promising approach to many cancers. We review the rationale and the current understanding of antiangiogenics and their therapeutic potential in combination with chemoradiotherapy. Finally, we offer a perspective on future research directions aimed at making this complex therapeutic approach successful in the clinic.
摘要
尽管仍处于临床开发的非常早期阶段，但抗血管生成药物与当代放化疗方案的联合应用已成为治疗多种癌症的一种可行且有前景的方法。我们回顾了抗血管生成药物的基本原理、当前认知及其与放化疗联合应用的治疗潜力。最后，我们对旨在使这种复杂治疗方法在临床上取得成功的未来研究方向提出了看法。
相似文献
1
Antiangiogenics: the potential role of integrating this novel treatment modality with chemoradiation for solid cancers.抗血管生成疗法：将这种新型治疗方式与实体癌放化疗相结合的潜在作用。
J Clin Oncol. 2007 Sep 10;25(26):4033-42. doi: 10.1200/JCO.2007.11.3985.
2
Antiangiogenics and radiotherapy.抗血管生成药物与放射疗法。
J Pharm Pharmacol. 2008 Aug;60(8):1029-36. doi: 10.1211/jpp.60.8.0009.
3
The interaction of radiation therapy and antiangiogenic therapy.放射治疗与抗血管生成治疗的相互作用。
Cancer J. 2008 Jul-Aug;14(4):207-13. doi: 10.1097/PPO.0b013e3181836af3.
4
[Angiogenesis inhibitors and radiotherapy].[血管生成抑制剂与放射疗法]
Praxis (Bern 1994). 2012 Aug 8;101(16):1031-7. doi: 10.1024/1661-8157/a001023.
5
Current state of knowledge regarding the use of antiangiogenic agents with radiation therapy.关于抗血管生成药物与放射治疗联合应用的知识现状。
Cancer Treat Rev. 2011 Oct;37(6):476-86. doi: 10.1016/j.ctrv.2011.03.004. Epub 2011 May 4.
6
Radiation combined with antiangiogenic and antivascular agents.放疗联合抗血管生成和抗血管药物。
Semin Radiat Oncol. 2006 Jan;16(1):45-50. doi: 10.1016/j.semradonc.2005.08.006.
7
Combining angiogenesis inhibition and radiotherapy: a double-edged sword.联合血管生成抑制和放疗：一把双刃剑。
Drug Resist Updat. 2012 Jun;15(3):173-82. doi: 10.1016/j.drup.2012.04.002. Epub 2012 May 4.
8
Therapeutic targeting of the tumor vasculature.肿瘤血管系统的治疗性靶向作用。
Semin Radiat Oncol. 2004 Jul;14(3):222-32. doi: 10.1016/j.semradonc.2004.04.009.
9
[Angiogenic inhibitors and radiotherapy: from the concept to the clinical trial].[血管生成抑制剂与放射治疗：从概念到临床试验]
Cancer Radiother. 2009 Oct;13(6-7):562-7. doi: 10.1016/j.canrad.2009.07.007. Epub 2009 Aug 19.
10
New anticancer agents and therapeutic strategies in development for solid cancers: a clinical perspective.实体癌新型抗癌药物及治疗策略的研发：临床视角
Expert Rev Anticancer Ther. 2004 Feb;4(1):53-60. doi: 10.1586/14737140.4.1.53.
引用本文的文献
1
New approaches to overcome radioresistance in glioblastoma: mechanisms, targets and role of innovative therapies, new particles and non-photon radiotherapy in 2024. A systematic review.2024年克服胶质母细胞瘤放射抗性的新方法：创新疗法、新粒子及非光子放疗的机制、靶点和作用。系统评价
Rep Pract Oncol Radiother. 2025 Jun 7;30(2):269-281. doi: 10.5603/rpor.105654. eCollection 2025.
2
PAK in Pancreatic Cancer-Associated Vasculature: Implications for Therapeutic Response.PAK 在胰腺癌相关血管中的作用：对治疗反应的影响。
Cells. 2023 Nov 23;12(23):2692. doi: 10.3390/cells12232692.
3
The Combination of Immune Checkpoint Blockade with Tumor Vessel Normalization as a Promising Therapeutic Strategy for Breast Cancer: An Overview of Preclinical and Clinical Studies.免疫检查点阻断联合肿瘤血管正常化作为一种有前途的乳腺癌治疗策略：临床前和临床研究综述。
Int J Mol Sci. 2023 Feb 6;24(4):3226. doi: 10.3390/ijms24043226.
4
Manipulation of immune‒vascular crosstalk: new strategies towards cancer treatment.免疫-血管相互作用的调控：癌症治疗的新策略
Acta Pharm Sin B. 2020 Nov;10(11):2018-2036. doi: 10.1016/j.apsb.2020.09.014. Epub 2020 Sep 28.
5
Risk factors for severe gastrointestinal toxicity in patients receiving palliative radiotherapy for metastatic bone tumors: association with the use of molecular-targeted agents.接受姑息性放疗的转移性骨肿瘤患者发生严重胃肠道毒性的危险因素：与分子靶向药物的使用相关。
J Radiat Res. 2020 Jul 6;61(4):629-634. doi: 10.1093/jrr/rraa035.
6
Ischemic stroke and intracranial hemorrhage in patients with recurrent glioblastoma multiforme, treated with bevacizumab.复发性多形性胶质母细胞瘤患者接受贝伐单抗治疗后的缺血性卒中和颅内出血。
J Neurooncol. 2017 Jul;133(3):571-579. doi: 10.1007/s11060-017-2467-z. Epub 2017 May 29.
7
Expression of Programmed Cell Death Protein 1 by Tumor-Infiltrating Lymphocytes and Tumor Cells is Associated with Advanced Tumor Stage in Patients with Esophageal Adenocarcinoma.肿瘤浸润淋巴细胞和肿瘤细胞程序性细胞死亡蛋白 1 的表达与食管腺癌患者的晚期肿瘤分期相关。
Ann Surg Oncol. 2017 Sep;24(9):2698-2706. doi: 10.1245/s10434-017-5858-7. Epub 2017 Apr 20.
8
Blockade of vascular endothelial growth factor receptors by tivozanib has potential anti-tumour effects on human glioblastoma cells.替沃扎尼布阻断血管内皮生长因子受体具有潜在的抗肿瘤作用，可抑制人胶质母细胞瘤细胞。
Sci Rep. 2017 Mar 13;7:44075. doi: 10.1038/srep44075.
9
Why one-size-fits-all vaso-modulatory interventions fail to control glioma invasion: in silico insights.为何一刀切的血管调节干预措施未能控制胶质瘤侵袭：计算机模拟的见解。
Sci Rep. 2016 Nov 23;6:37283. doi: 10.1038/srep37283.
10
Nanomedicines for Endothelial Disorders.用于内皮疾病的纳米药物。
Nano Today. 2015 Dec 1;10(6):759-776. doi: 10.1016/j.nantod.2015.11.009.
本文引用的文献
1
Bevacizumab, oxaliplatin, and capecitabine with radiation therapy in rectal cancer: Phase I trial results.贝伐单抗、奥沙利铂和卡培他滨联合放疗用于直肠癌：I期试验结果。
Int J Radiat Oncol Biol Phys. 2007 Jun 1;68(2):472-8. doi: 10.1016/j.ijrobp.2007.02.001.
2
Complete pathological response to bevacizumab and chemoradiation in advanced rectal cancer.晚期直肠癌对贝伐单抗及放化疗的完全病理缓解
Nat Clin Pract Oncol. 2007 May;4(5):316-21. doi: 10.1038/ncponc0813.
3
A protocol for phenotypic detection and enumeration of circulating endothelial cells and circulating progenitor cells in human blood.一种用于检测和计数人血中循环内皮细胞和循环祖细胞表型的方案。
Nat Protoc. 2007;2(4):805-10. doi: 10.1038/nprot.2007.111.
4
Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: insights from a mathematical model.抗血管生成疗法实现血管正常化对间质高血压、肿瘤周围水肿和淋巴转移的影响：来自数学模型的见解
Cancer Res. 2007 Mar 15;67(6):2729-35. doi: 10.1158/0008-5472.CAN-06-4102.
5
Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma.贝伐单抗与伊立替康治疗复发性恶性胶质瘤的II期试验。
Clin Cancer Res. 2007 Feb 15;13(4):1253-9. doi: 10.1158/1078-0432.CCR-06-2309.
6
Effect of bevacizumab on radiation necrosis of the brain.贝伐单抗对脑放射性坏死的影响。
Int J Radiat Oncol Biol Phys. 2007 Feb 1;67(2):323-6. doi: 10.1016/j.ijrobp.2006.10.010.
7
AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.AZD2171是一种泛血管内皮生长因子（VEGF）受体酪氨酸激酶抑制剂，可使胶质母细胞瘤患者的肿瘤血管正常化并减轻水肿。
Cancer Cell. 2007 Jan;11(1):83-95. doi: 10.1016/j.ccr.2006.11.021.
8
Sorafenib in advanced clear-cell renal-cell carcinoma.索拉非尼治疗晚期透明细胞肾细胞癌
N Engl J Med. 2007 Jan 11;356(2):125-34. doi: 10.1056/NEJMoa060655.
9
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.舒尼替尼与干扰素α治疗转移性肾细胞癌的对比研究
N Engl J Med. 2007 Jan 11;356(2):115-24. doi: 10.1056/NEJMoa065044.
10
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.单独使用紫杉醇-卡铂或联合贝伐单抗治疗非小细胞肺癌。
N Engl J Med. 2006 Dec 14;355(24):2542-50. doi: 10.1056/NEJMoa061884.
Zotero 插件